NRBO

NeuroBo Pharmaceuticals, Inc.

4.66 USD
-0.34 (-6.80%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

NeuroBo Pharmaceuticals, Inc. stock is up 18.88% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 July’s closed higher than June.

About NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial. NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment.